|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
National Crisis Supercedes Coverage Debate
Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.
Advertisement
Articles in this issue
about 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
PBMs: Merck-Medco in the Hot Seatabout 24 years ago
A Five-Year Forecast: Clear Seas Ahead?about 24 years ago
Weak Bones, Strong Marketabout 24 years ago
Approvals: Novartis’ Silver Liningabout 24 years ago
Pfizer and others Pitch Inabout 24 years ago
Oncology: EMEA Approval Lagsabout 24 years ago
Illegal Sales in Indiaabout 24 years ago
Health Plan Premiums: Pharma Takes the Blameabout 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
